Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.
Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will be presenting the data during the New Therapeutic Targets for Diabetes session. This was a randomized, double-blind, placebo-controlled Phase 2a study designed to assess the safety and tolerability of multiple bedtime doses of the ORMD-0801 oral insulin formulation in adult Type 2 diabetes patients inadequately controlled with diet alone or diet and metformin. Preliminary results were announced by the company on January 30th of this year.
Presentation Details
Title: The Tolerability and Efficacy of Oral Insulin in Type 2 Diabetes Patients: A Pilot Clinical Study
Time: 3:15 on April 24th 2014
Location: Hyatt Regency Cambridge, MA
New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetes